Earnings growth in the S&P 500 is currently concentrated in the technology and energy sectors, fueled by AI advancements and commodity price spikes from Middle East conflicts. However, much of this profit surge appears temporary or overstated, with key companies showing weak or negative free cash flow and large off-balance-sheet liabilities. Aggressive accounting practices and ongoing construction projects may inflate reported earnings, masking underlying economic weakness as GDP growth remains modest at 1.2%. This bifurcated earnings growth raises questions about the sustainability of recent gains.
The earnings growth outlook for 2026's S&P 500 is increasingly seen as illusionary. For readers following the technology sector, here is Pluang's market snapshot as of Sep 21, 2026 23:33 WIB: out of 150 priced US tech stocks, 129 rose and 21 fell today. Notable gainers include ARM with a 15.88% increase to USD 319.39, FSLY up 15.59% at USD 27.58, and DOCN rising 13.59% to USD 147.82, with typical hold times ranging from 26 to 43 days on Pluang.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Fannie Mae completed its 28th sale of non-performing loans, selling 919 loans totaling $203.3 million in unpaid principal to Residential Credit Opportunities Trust IX-D. The loans have an average size of $221,222 and a weighted average interest rate ...
Sergey Nazarov, co-founder of Chainlink, will speak at Sibos 2026, a major financial conference, across three sessions covering tokenized assets, intelligent money, and interoperable finance. The event, held from September 28 to October 1 in Miami Be...
SanDisk shares fell 2% while the broader memory sector, including peers Micron and Western Digital, saw gains of 3% and 0.8% respectively. This divergence occurred without any company-specific news, suggesting profit-taking or position trimming after...
A class action lawsuit has been filed against Ardelyx, Inc. for allegedly misleading investors about the commercial performance and growth prospects of its key drugs, IBSRELA and XPHOZAH, between January 2025 and August 2026. The lawsuit claims Ardel...
